Lauren Marcath
Pharm.D.
Education
- Bachelor of Science, University of Michigan
- Doctor of Pharmacy, University of Michigan
About Me
I am originally from southeastern Michigan and became interested in pharmacy in high school when I had the opportunity to shadow pharmacists at Henry Ford Hospital in Detroit. That experience showed me how impactful pharmacists can be to patient care through their drug expertise. I attended the University of Michigan where I received my Bachelor of Science and Doctor of Pharmacy degrees. After receiving my Doctor of Pharmacy, I stayed at the University of Michigan as a Clinical Pharmacy Translational Science Post-Doctoral Fellow where I worked in the Hertz lab focusing on drug-drug interactions and pharmacogenomics.
I greatly enjoyed my time during my fellowship spending time teaching and conducting research, which led me to pursue a career in academia. I continue to conduct research in pharmacogenomics and drug-drug interactions. I currently teach in Introduction to Therapeutic Agents: Top 200 (Pharmacy 507), Health Care Systems (Pharmacy 516), and Quality Assurance and Patient Safety (Pharmacy 559).
In my spare time I like to…
I enjoy hiking and kayaking with my husband. I also like spending time with my two dogs: a corgi and a rescue dog.
Why WSU?
I really liked the culture of WSU and the emphasis placed on teaching excellence. It was a strong match for my interests and priorities. I also had always wanted to move out west to be closer to the mountains for hiking and skiing.
Selected Publications
Marcath LA, Coe TD, Shakeel F, Reynolds E, Bayuk M, Haas S, Redman BG, Wong SF, Hertz DL. Improvement Initiative to Develop and Implement a Tool for Detecting Drug-Drug Interactions During Oncology Clinical Trial Enrollment Eligibility Screening. J Patient Saf. 2020 Sep 29. doi: 10.1097/PTS.0000000000000772. Epub ahead of print. PMID: 33003175.
Chen Y, Fang F, Kidwell KM, Vangipuram K, Marcath LA, Gersch CL, Rae JM, Hayes DF, Lavoie Smith EM, Henry NL, Beutler AS, Hertz DL. Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy. Pharmacogenomics. 2020;21(12):841-851. doi:10.2217/pgs-2020-0053
Shakeel F, Fang F, Kidwell KM, Marcath LA, Hertz DL. Comparison of eight screening tools to detect interactions between herbal supplements and oncology agents [published online ahead of print, 2020 Feb 19]. J Oncol Pharm Pract. 2020;1078155220905009. doi:10.1177/1078155220905009.
Marcath LA, Kidwell KM, Vangipuram K, Gersch CL, Rae JM, Burness ML, Griggs JJ, Van Poznak C, Hayes DF, Smith EML, Henry NL, Beutler AS, Hertz DL. Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathy. Br J Clin Pharmacol. 2020 May;86(5):880-890. doi: 10.1111/bcp.14192. Epub 2020 Feb 4. PMID: 31823378; PMCID: PMC7163383.
Marcath LA, Pasternak AL, Hertz DL. Challenges to assess substrate-dependent allelic effects in CYP450 enzymes and the potential clinical implications. Pharmacogenomics J. 2019 Dec;19(6):501-515. doi: 10.1038/s41397-019-0105-1. Epub 2019 Oct 15. PMID: 31616046.
Marcath LA, Kidwell KM, Robinson AC, Vangipuram K, Burness ML, Griggs JJ, Poznak CV, Schott AF, Hayes DF, Henry NL, Hertz DL. Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure. Pharmacogenomics. 2019 Jan;20(2):95-104. doi: 10.2217/pgs-2018-0162. Epub 2018 Dec 6. PMID: 30520341; PMCID: PMC6562943.
Marcath LA, Coe TD, Hoylman EK, Redman BG, Hertz DL. Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials. BMC Cancer. 2018 Nov 22;18(1):1155. doi: 10.1186/s12885-018-5076-0. PMID: 30466416; PMCID: PMC6249716.
Marcath LA, Xi J, Hoylman EK, Kidwell KM, Kraft SL, Hertz DL. Comparison of Nine Tools for Screening Drug-Drug Interactions of Oral Oncolytics. J Oncol Pract. 2018 Jun;14(6):e368-e374. doi: 10.1200/JOP.18.00086. Epub 2018 May 22. PMID: 29787332.
Marcath LA, Deal AM, Van Wieren E, Danko W, Walko CM, Ibrahim JG, Weck KE, Jones DR, Desta Z, McLeod HL, Carey LA, Irvin WJ Jr, Hertz DL. Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment. Pharmacogenet Genomics. 2017 Nov;27(11):402-409. doi: 10.1097/FPC.0000000000000311. PMID: 28877533; PMCID: PMC5659294.